C4 Therapeutics Stock Performance
| CCCC Stock | USD 6.44 0.03 0.47% |
On a scale of 0 to 100, C4 Therapeutics holds a performance score of 12. The firm owns a Beta (Systematic Risk) of 3.22, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, C4 Therapeutics will likely underperform. Please check C4 Therapeutics' mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to make a quick decision on whether C4 Therapeutics' current price history will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in C4 Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of rather conflicting fundamental indicators, C4 Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.47 | Five Day Return (0.77) | Year To Date Return (1.23) | Ten Year Return (74.74) | All Time Return (74.74) |
1 | Acquisition by Grogan Donna Roy of 32500 shares of C4 Therapeutics at 4.05 subject to Rule 16b-3 | 06/20/2024 |
2 | Acquisition by Grogan Donna Roy of 26000 shares of C4 Therapeutics at 3.61 subject to Rule 16b-3 | 06/21/2024 |
3 | C4 Therapeutics, Inc. Given Average Recommendation of Hold by Brokerages - Defense World | 06/28/2024 |
4 | Acquisition by Anderson Kenneth Carl of 2320 shares of C4 Therapeutics at 4.85 subject to Rule 16b-3 | 07/01/2024 |
5 | Disposition of 6191 shares by Reyno Leonard of C4 Therapeutics at 5.0 subject to Rule 16b-3 | 07/10/2024 |
6 | C4 Therapeutics, Inc. Reports Q2 Loss, Tops Revenue Estimates | 08/01/2024 |
7 | Analysts Revenue Estimates For C4 Therapeutics, Inc. Are Surging Higher | 08/09/2024 |
8 | C4 Therapeutics Announces European Society for Medical Oncology Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presen... | 08/14/2024 |
9 | BMO stock gets Outperform rating on C4 Therapeutics - Investing.com | 08/20/2024 |
10 | C4 Therapeutics to Participate in Upcoming September Investor Conferences | 08/29/2024 |
11 | C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V60... | 09/13/2024 |
| Begin Period Cash Flow | 29.8 M |
CCCC |
C4 Therapeutics Relative Risk vs. Return Landscape
If you would invest 408.00 in C4 Therapeutics on June 18, 2024 and sell it today you would earn a total of 236.00 from holding C4 Therapeutics or generate 57.84% return on investment over 90 days. C4 Therapeutics is currently generating 0.905% in daily expected returns and assumes 5.8838% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than CCCC, and 82% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
C4 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for C4 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as C4 Therapeutics, and traders can use it to determine the average amount a C4 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1538
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CCCC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.88 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.91 actual daily | 18 82% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average C4 Therapeutics is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of C4 Therapeutics by adding it to a well-diversified portfolio.
C4 Therapeutics Fundamentals Growth
CCCC Stock prices reflect investors' perceptions of the future prospects and financial health of C4 Therapeutics, and C4 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CCCC Stock performance.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (1.79) % | ||||
| Current Valuation | 250.85 M | ||||
| Shares Outstanding | 69.34 M | ||||
| Price To Book | 1.81 X | ||||
| Price To Sales | 15.20 X | ||||
| Revenue | 20.76 M | ||||
| Gross Profit | (86.75 M) | ||||
| EBITDA | (131.29 M) | ||||
| Net Income | (132.49 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 70.98 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 3.59 X | ||||
| Cash Flow From Operations | (106.84 M) | ||||
| Earnings Per Share | (1.90) X | ||||
| Market Capitalization | 446.54 M | ||||
| Total Asset | 376.45 M | ||||
| Retained Earnings | (528.38 M) | ||||
| Working Capital | 228.42 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
About C4 Therapeutics Performance
By analyzing C4 Therapeutics' fundamental ratios, stakeholders can gain valuable insights into C4 Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if C4 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if C4 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -3.4 K | -3.2 K | |
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.42) | (0.44) | |
| Return On Assets | (0.35) | (0.37) | |
| Return On Equity | (0.54) | (0.51) |
Things to note about C4 Therapeutics performance evaluation
Checking the ongoing alerts about C4 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for C4 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| C4 Therapeutics is way too risky over 90 days horizon | |
| C4 Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 20.76 M. Net Loss for the year was (132.49 M) with loss before overhead, payroll, taxes, and interest of (86.75 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (106.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29. | |
| Over 88.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology Congress 2024 |
- Analyzing C4 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether C4 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining C4 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating C4 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of C4 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of C4 Therapeutics' stock. These opinions can provide insight into C4 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |